Literature DB >> 28155141

Compliance to The Joint Commission proposed Core Measure set on osteoporosis-associated fracture: review of different secondary fracture prevention programs in an open medical system from 2010 to 2015.

Ma Conchitina Fojas1, Lauren T Southerland2, Laura S Phieffer3, Julie A Stephens4, Tanya Srivastava5, Steven W Ing5.   

Abstract

There are care gaps in the evaluation and treatment of osteoporosis after a fragility fracture. The Joint Commission is considering adoption of core measures. We compared compliance between two secondary fracture prevention programs in our institution. Incorporating strengths of both may provide the best outcomes for secondary fracture prevention.
PURPOSE: There are significant care gaps in the evaluation and treatment of osteoporosis after occurrence of fragility fracture. The Joint Commission is considering adoption of a core measure set on osteoporosis-associated fractures, including laboratory assessment, bone density testing, and osteoporosis pharmacologic therapy. We compared compliance to these proposed measures between two secondary fracture prevention programs in patients hospitalized for acute fracture in an open medical system.
METHODS: We conducted a retrospective, single center medical records review of a nurse practitioner-led Fracture Liaison Service (FLS), a physician-led Fracture Prevention Program (FPP), and a historical time without any secondary fracture prevention program (Usual Care) for baseline care. Primary outcomes were the completion of five laboratory tests (calcium, 25-hydroxy vitamin D, renal function, liver function, and complete blood count), order placement and completion of dual x-ray absorptiometry (DXA) scan within 3 months, prescription of osteoporosis medication within 3 months, and medication adherence at 6 months after hospital discharge.
RESULTS: Completion of all five laboratory tests was higher in FPP versus FLS (84.7 vs. 36.9%, p < 0.001). DXA scan completion was higher in FPP than FLS but not statistically significant (66.7 vs. 54.9%, p = 0.11). Medication prescription at 3 months and adherence at 6 months were significantly higher in FPP versus FLS (65.3 vs. 24.0%, p < 0.001 and 70.8 vs. 27.7%, p < 0.001, respectively).
CONCLUSION: Incorporating strengths of both FLS (care coordination) and FPP (physician direction) may provide the best outcomes for secondary fracture prevention by ensuring laboratory and DXA testing and initiating osteoporosis medication.

Entities:  

Keywords:  Fracture Liaison Service; Secondary osteoporotic fracture prevention

Mesh:

Substances:

Year:  2017        PMID: 28155141     DOI: 10.1007/s11657-017-0307-6

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  4 in total

Review 1.  Quality Measures and Quality Improvement Initiatives in Osteoporosis-an Update.

Authors:  S French; S Choden; Gabriela Schmajuk
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

Review 2.  Implementing models of care for musculoskeletal conditions in health systems to support value-based care.

Authors:  Robyn Speerin; Christopher Needs; Jason Chua; Linda J Woodhouse; Margareta Nordin; Rhona McGlasson; Andrew M Briggs
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-07-25       Impact factor: 4.098

3.  Effects of the falls and fractures clinic as an integrated multidisciplinary model of care in Australia: a pre-post study.

Authors:  Fernando Gomez; Carmen Lucia Curcio; Sharon Lee Brennan-Olsen; Derek Boersma; Steven Phu; Sara Vogrin; Pushpa Suriyaarachchi; Gustavo Duque
Journal:  BMJ Open       Date:  2019-07-29       Impact factor: 2.692

4.  The interdisciplinary fracture liaison service improves health-related outcomes and survival of older adults after hip fracture surgical repair.

Authors:  Carmelinda Ruggiero; Marta Baroni; Giuseppe Rocco Talesa; Alessandro Cirimbilli; Valentina Prenni; Valentina Bubba; Luca Parretti; Riccardo Bogini; Giuliana Duranti; Auro Caraffa; Virginia Boccardi; Patrizia Mecocci; Giuseppe Rinonapoli
Journal:  Arch Osteoporos       Date:  2022-10-17       Impact factor: 2.879

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.